التفاصيل البيبلوغرافية
| العنوان: |
Clinical Response to Anti–Programmed Death 1 After Response and Subsequent Progression on Anti–Programmed Death Ligand 1 Therapy. |
| المؤلفون: |
Castellanos, Emily H.1 (AUTHOR), Feld, Emily1 (AUTHOR), Estrada, Monica V.1 (AUTHOR), Sanders, Melinda E.1 (AUTHOR), Massion, Pierre P.1 (AUTHOR), Johnson, Douglas B.1 (AUTHOR), Balko, Justin M.1 (AUTHOR) justin.balko@vanderbilt.edu, Horn, Leora1 (AUTHOR) |
| المصدر: |
JCO Precision Oncology. 2017, Vol. 1 Issue 1, p1-9. 9p. |
| مصطلحات موضوعية: |
*NON-small-cell lung carcinoma, *AXILLARY lymph node dissection |
| مستخلص: |
After his initial disease progression while receiving anti-PD-L1 therapy, repeat biopsy demonstrated no tumor PD-L1 staining (with limited stromal PD-L1 positivity), and PD-L2 remained strongly positive (70%; Fig 1C). This finding suggests that the significance of PD-L2 positivity in response to PD-L1 or PD-1 targeted therapies may be a useful subject of study. Although anecdotal, this case report demonstrates an important clinical finding: patients who become resistant to anti-PD-L1 may still benefit from PD-1 targeted therapies, possibly due to a switch from dependency on PD-L1 to PD-L2 for maintenance of immunosuppression. However, the presence of consistently high PD-L2 staining argues against a direct mechanism of PD-L2-mediated de novo resistance to anti-PD-L1 therapy. [Extracted from the article] |
| قاعدة البيانات: |
Academic Search Index |
